about
Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosisThe peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidationResistance of M. leprae to quinolones: a question of relativity?Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in MiceEvaluation of data quality in a laboratory-based surveillance of M. tuberculosis drug resistance and impact on the prevalence of resistance: France, 2004.[Resistance to antituberculosis drug in France; data provided by the Azay-Mycobacteria network and the National Reference Center on Mycobacteria].A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts.Mycobacterial infection of breast prosthesis--a conservative treatment: a case reportClonal relationship and differentiation among Mycobacterium abscessus isolates as determined using the semiautomated repetitive extragenic palindromic sequence PCR-based DiversiLab system.Rapid identification of mycobacterial whole cells in solid and liquid culture media by matrix-assisted laser desorption ionization-time of flight mass spectrometry.Identification and genotyping of Mycobacterium tuberculosis complex species by use of a SNaPshot Minisequencing-based assay.Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates.Unbiased estimation of mutation rates under fluctuating final counts.Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based single nucleotide polymorphism genotyping assay using iPLEX gold technology for identification of Mycobacterium tuberculosis complex species and lineagesEfficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine modelElectronic sensors for assessing interactions between healthcare workers and patients under airborne precautionsNovel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosisAssessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing.Comparison of a semiautomated commercial repetitive-sequence-based PCR method with spoligotyping, 24-locus mycobacterial interspersed repetitive-unit-variable-number tandem-repeat typing, and restriction fragment length polymorphism-based analysis oPerformance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistance.Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis.Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones.Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosisMolecular Analysis of the embCAB Locus and embR Gene Involved in Ethambutol Resistance in Clinical Isolates of Mycobacterium tuberculosis in France.Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis.Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains.Contact tracing of passengers exposed to an extensively drug-resistant tuberculosis case during an air flight from Beirut to Paris, October 2006.Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.Evaluation of the Fluo-RAL module for detection of tuberculous and nontuberculous acid-fast Bacilli by fluorescence microscopyRifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis.Selection of Resistance to Clarithromycin in Mycobacterium abscessus SubspeciesMolecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.[Utility of molecular tools in diagnosis, treatment, and epidemiology of mycobacterial infections]Multidrug and extensively drug-resistant tuberculosis.
P50
Q28477317-73F5B0A0-F45E-4D2A-9FBD-68F930712BACQ28486366-6BD96110-B9D2-4AFA-B3D9-293EB23D1463Q28535115-D968312C-AEE7-42E9-AAAE-C8BC9B8296C2Q28552736-33FAD301-849C-4DDE-A936-DF612355444AQ31137273-B52B00B6-A257-46BC-96D8-C8B81D86421AQ31161321-030DC292-3DE3-4B66-9C52-399985A5B82EQ33379045-0FDE90CB-427A-40E7-A268-1D3714252EEFQ33420381-B79FA565-E353-40A5-A719-DA043762B957Q33599268-D05DBD1F-E917-4BDB-96EC-4CB90A2627C8Q33703455-2B504ABD-A905-448F-A128-392EA0F146A3Q33718176-97B4C124-13CB-49E4-BE50-72E71AA525A4Q33827004-CC278DD3-C4FA-41B7-B5A4-B1E3C9A1076BQ33827163-22C428D2-17D1-4224-867D-E541E1CE7D76Q33837919-A0B54639-82B4-44D2-88ED-3FAEA50DB70EQ33953281-40C24AF0-6241-454D-81E8-D7F5EF00D2A0Q34077125-6A11E707-7ABF-421D-86CF-28C4AC4CBAF4Q34290003-1D1C5CEA-CFFD-42BF-82BD-307B6FDBA869Q34291396-03A364C1-6F35-4F35-AE88-022EA0EBEA4DQ34301585-AA570FC0-33F6-4B6A-8110-5676476AD2BAQ34483621-B39D6415-453C-4C5B-B622-C84D63332251Q34528945-8517F7B5-C447-43D3-8E2D-59372E184270Q35036110-474214E6-38D3-4D5F-9D95-DD48129CCCCEQ35073562-844551BF-BDF8-4939-8522-E3A27FEB9622Q35076978-C68F0F78-EF33-4045-96AE-F637DE9A0A2CQ35127770-9648815F-0D7F-4665-BDF6-81442931D0BEQ35215435-F1C9EF9B-E106-4452-8B05-FC0F925C74ABQ35647811-D8D4DE7C-79DA-4423-AFD7-D823DF57D9A7Q35859945-B1CFB536-8C71-4278-9260-7C900058F5B8Q35867476-EF9EA806-966B-4504-9419-C9F0856A8FDBQ36047567-689F350B-32A6-446C-A38D-6DFA45BB0784Q36402705-2B5EDC17-1B13-43E2-93E9-85D7AA6EB481Q36933151-000085E7-9671-4E56-8F22-F546E715AD55Q37027670-C4476D86-52AE-4213-84FA-ECC24B34870FQ37124036-243E3AF5-9058-4D13-BA61-FE61A767D9F5Q37264239-A470692B-B33A-4F6E-8BB9-5B720DA36890Q37502309-290BA84E-422A-4CF3-974C-F88D28EA743FQ37538786-E718F70B-A9D6-4BB4-A13B-2BB4BDA01FAFQ37612943-F11A1C0D-23CA-47A9-9BF5-13A538F09B21Q38490358-61E20CB7-B570-4691-A0A2-39D4D92F3398Q38956830-E41AEC01-3C8F-4159-BC93-DBAEEF396F3B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicolas Veziris
@ast
Nicolas Veziris
@en
Nicolas Veziris
@es
Nicolas Veziris
@nl
Nicolas Veziris
@sl
type
label
Nicolas Veziris
@ast
Nicolas Veziris
@en
Nicolas Veziris
@es
Nicolas Veziris
@nl
Nicolas Veziris
@sl
prefLabel
Nicolas Veziris
@ast
Nicolas Veziris
@en
Nicolas Veziris
@es
Nicolas Veziris
@nl
Nicolas Veziris
@sl
P1053
O-9783-2017
P106
P21
P31
P3829
P496
0000-0001-5660-6544